2024
CHAPTER 1 Introduction
Ortiz G, Garcia-Tsao G. CHAPTER 1 Introduction. 2024, 1-6. DOI: 10.1016/b978-0-323-87479-3.00010-7.ChaptersChronic liver diseasePortal hypertensionSustained liver injurySignificant portal hypertensionHealth care utilizationHepatic vein catheterizationStaging of fibrosisBurden of diseaseMost complicationsLiver injuryCare utilizationLiver diseaseVein catheterizationCirrhotic stageLiver stiffnessInvasive proceduresTime of interpretationDiffuse depositionSignificant causeAge groupsNoninvasive meansFibrous tissueSmall riskInterobserver variabilityGold standard
2023
The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease
Jirapinyo P, Thompson C, Garcia-Tsao G, Zucker S, Ryou M. The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Endoscopy 2023, 56: 56-62. PMID: 37532114, DOI: 10.1055/a-2146-8857.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseEndoscopic gastric plicationAdvanced chronic liver diseaseFatty liver diseasePortosystemic pressure gradientChronic liver diseaseLiver diseaseTotal weight lossGastric plicationNoninvasive testsBaseline median body-mass indexMedian body mass indexPercent total weight lossWeight lossProportion of patientsProspective pilot studyBody mass indexLiver stiffness measurementWeight loss proceduresGoal of therapyHepatic decompensationSecondary outcomesPrimary outcomeMass indexPatientsControversies regarding albumin therapy in cirrhosis.
Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis. Hepatology 2023 PMID: 37540192, DOI: 10.1097/hep.0000000000000521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSpontaneous bacterial peritonitisBacterial peritonitisAcute kidney injuryLarge-volume paracentesisSerum albumin levelChronic liver diseaseUse of albuminHepatorenal syndromeAdvanced cirrhosisAlbumin infusionKidney injuryAlbumin therapyAlbumin levelsAlbumin useProinflammatory stateLiver diseasePatient selectionVolume overloadPoor outcomeHigh oxidative stressCirrhosisPathophysiological relevanceOxidative stressPeritonitisAlbumin
2021
Baveno VII – Renewing consensus in portal hypertension
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Faculty B, Abraldes J, Albillos A, Baiges A, Bajaj J, Bañares R, Barrufet M, Benajiba L, Berzigotti A, Bureau C, Calvaruso V, Cardenas A, D’Amico G, De Gottardi A, Dell’Era A, Escorsell A, Fallowfield J, Ferral H, Francque S, Gaba R, Garcia-Pagàn J, Genescà J, Rodrigues S, Gracia-Sancho J, Han G, Hernandez-Gea V, Jia J, Kiladjian J, Krag A, Laleman W, La Mura V, Lens S, Luo X, Mandorfer M, Murad S, Paradis V, Patch D, Piano S, Pinzani M, Plessier A, Primignani M, Procopet B, Rautou P, Rudler M, Sarin S, Schepis F, Senzolo M, Shah V, Shukla A, Tandon P, Tellez L, Thabut D, Thiele M, Trebicka J, Tripathi D, Tsochatzis E, Turco L, Turon F, Valla D, Villanueva C, Wanless I, Yoshiji H. Baveno VII – Renewing consensus in portal hypertension. Journal Of Hepatology 2021, 76: 959-974. PMID: 35120736, PMCID: PMC11090185, DOI: 10.1016/j.jhep.2021.12.022.Peer-Reviewed Original ResearchConceptsPortal hypertensionAdvanced chronic liver diseaseHepatic venous pressure gradientAcute bleeding episodeSignificant portal hypertensionVenous pressure gradientChronic liver diseaseSplanchnic vein thrombosisCourse of cirrhosisRisk of deathNon-invasive toolBleeding episodesCompensated cirrhosisFurther decompensationVein thrombosisLiver diseaseBaveno VIVascular disordersFirst episodeHypertensionPersonalized careMedical literatureTherapeutic needsGold standardCirrhosisO-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES
Ragazzo T, Garcia-Tsao G, Mazo D, Ziteli P, Oliveira C, Singer J, Carrilho F, Pessoa M. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES. Annals Of Hepatology 2021, 24: 100493. DOI: 10.1016/j.aohep.2021.100493.Peer-Reviewed Original ResearchLiver stiffness measurementF3/F4Viral eliminationLiver fibrosisF0-1Advanced liver fibrosis/cirrhosisLiver fibrosis/cirrhosisChronic liver diseaseFibrosis/cirrhosisNon-invasive testsNon-invasive assessmentHCV cureAntiviral therapyClinical outcomesLiver diseaseHepatic fibrosisClinical usefulnessPatientsPredictive valueRelevant outcomesDecompensationLarger studyFibrosisLSM increaseStiffness measurementSACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective study
2020
Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation
Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia‐Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation. Hepatology 2020, 72: 1819-1837. PMID: 32740969, PMCID: PMC7435542, DOI: 10.1002/hep.31491.Peer-Reviewed Original ResearchConceptsClinical researchInvestigational productAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicChronic liver diseaseLong-term followCoronavirus 2 pandemicClinical trial designImplementation of telemedicineHepatitis BLiver diseaseLaboratory monitoringClinical careTrial designCoronavirus disease 2019 (COVID-19) researchNatural historyCompletion of studyTherapeutic developmentNational InstituteCOVID-19 pandemicHepatologyOngoing studiesDiseaseIndustry fundingPandemic
2019
Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis
Sayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia‐Tsao G. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis. Liver International 2019, 39: 2061-2065. PMID: 31365178, PMCID: PMC11340272, DOI: 10.1111/liv.14203.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusHepatitis C virusPresence of cirrhosisViral eliminationTreatment completionPlatelet countLiver fibrosisNegative HCV RNAAbsence of cirrhosisChronic HCV infectionNon-invasive scoresPlatelet count increaseChronic liver diseaseHCV infectionPortal hypertensionHCV RNAAntiviral treatmentFibrosis scoreLiver diseaseC virusFibrosis stageRetrospective analysisCirrhosisPatientsFibrosisPrioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Abraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, Bosch J, Garcia‐Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology 2019, 69: 1287-1299. PMID: 30318607, PMCID: PMC11090176, DOI: 10.1002/hep.30314.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseasePortal pressurePortal hypertensionLiver diseaseCardiac output leadsCause of cirrhosisCirrhotic portal hypertensionChronic liver diseaseFatty liver diseasePortal venous inflowIntrahepatic vascular resistanceRisk of decompensationEarly clinical studiesCirrhosis decompensationSplanchnic vasodilationVascular resistancePharmacological therapyEtiological treatmentVenous inflowCirrhosis resultsSuch therapyClinical trialsBest therapyClinical studiesCirrhosis
2013
Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise
Belcher JM, Parikh CR, Garcia–Tsao G. Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise. Clinical Gastroenterology And Hepatology 2013, 11: 1550-1558. PMID: 23583467, PMCID: PMC3840046, DOI: 10.1016/j.cgh.2013.03.018.Commentaries, Editorials and LettersConceptsCreatinine levelsSodium levelsRenal Disease Study equationPacked red blood cellsTotal serum bilirubin levelsAcute kidney injurySerum creatinine levelsMental status changesRenal tubular epithelial cellsSerum sodium levelsChronic liver diseaseGlomerular filtration rateInternational normalization ratioModification of DietIntensive care unitUrine sodium levelSerum bilirubin levelsFresh frozen plasmaChronic alcohol abuseTubular epithelial cellsHepatitis CKidney injuryRed blood cellsBlood pressureFractional excretion
2003
553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis?
Nagula S, Jain D, Groszmann R, Garcia-Tsao G. 553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis? Hepatology 2003, 38: 426-427. DOI: 10.1016/s0270-9139(03)80595-5.Peer-Reviewed Original Research
2000
Portal hypertension
Garcia-Tsao G. Portal hypertension. Current Opinion In Gastroenterology 2000, 16: 282-289. PMID: 17023887, DOI: 10.1097/00001574-200005000-00012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsComplications of cirrhosisPortal hypertensionHyperdynamic circulationHepatic insufficiencyCirrhosis portal hypertensionChronic liver diseaseHepatorenal syndromeRenal vasoconstrictionSinusoidal hypertensionGastroesophageal varicesPeripheral vasodilatationHemodynamic abnormalitiesPortosystemic encephalopathyLiver diseaseSodium retentionNeurohumoral systemsHypertensionCirrhosisMajor syndromesVasodilatationComplicationsSyndromeInsufficiencyVaricesVasoconstriction
1999
Portal hypertension
Garcia-Tsao G. Portal hypertension. Current Opinion In Gastroenterology 1999, 15: 260-269. PMID: 17023954, DOI: 10.1097/00001574-199905000-00012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsComplications of cirrhosisPortal hypertensionHyperdynamic circulationHepatic insufficiencyChronic liver diseaseRenal vasoconstrictionSinusoidal hypertensionGastroesophageal varicesHepatopulmonary syndromePeripheral vasodilatationHemodynamic abnormalitiesPortosystemic encephalopathyLiver diseaseSodium retentionPulmonary circulationNeurohumoral systemsCirrhosisHypertensionMajor syndromesVasodilatationSyndrome resultsComplicationsEnd stageSyndromeInsufficiency
1997
Portal hypertension
Garcia-Tsao G. Portal hypertension. Current Opinion In Gastroenterology 1997, 13: 263-270. DOI: 10.1097/00001574-199705000-00013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsComplications of cirrhosisPortal hypertensionHepatic insufficiencyChronic liver diseaseSpontaneous bacterial peritonitisInsufficiency contributesVariceal hemorrhageCirrhotic patientsPortosystemic encephalopathyBacterial peritonitisLiver diseaseHypertensionMajor syndromesCirrhosisComplicationsEnd stageInsufficiencyVaricesPeritonitisAscitesHemorrhagePatientsEncephalopathyPathophysiologySyndrome
1981
Relationship between blood lactic acid and serum proline in alcoholic liver cirrhosis
Kershenobich D, García-Tsao G, Saldana S, Rojkind M. Relationship between blood lactic acid and serum proline in alcoholic liver cirrhosis. Gastroenterology 1981, 80: 1012-1015. PMID: 7202961, DOI: 10.1016/0016-5085(81)90074-3.Peer-Reviewed Original ResearchConceptsBlood lactic acidAlcoholic cirrhotic patientsAlcoholic liver diseaseAlcoholic cirrhoticsCirrhotic patientsLiver diseaseSerum prolineBlood lactateAlcoholic liver cirrhosisChronic liver diseaseNonalcoholic cirrhotic patientsNon-alcoholic volunteersMean control valueLiver cirrhosisAlcohol intakeAlcoholic patientsLiver damageLiver fibrogenesisAcute intoxicationCirrhoticsPatientsNormal valuesPossible markerControl valuesInhibitory effect